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SUMMARY 
Technology, procedures, devices and drugs account for 
50-75% of the increase in healthcare costs. The UK 
National Health Service (NHS) executive is keen to 
promote the provision of high-technology care at home 
as part of its commitment to providing high-quality 
care in the community. The provision of parenteral 
antimicrobial therapy in the community lends itself to 
this philosophy. Despite this, and though outpatient 
and home parenteral antibiotic therapy (OHPAT) is 
a n  accepted ‘standard of care’ for managing many 
infections in North America, Europe has been slow 
to respond to this innovation in healthcare delivery. 
At present, a few enthusiasts are responding to this 
challenge but most infections requiring parenteral 
therapy are treated in the inpatient hospital setting. 
Currently, OHPAT in the UK has low government 
priority and existing activity is poorly coordinated and 
under-resourced. However, emergency medical admis- 
sions have risen by 50% since 1984 and now account 
for almost half of all NHS admissions. This in turn has 
necessitated an emergency cash boost for the NHS, and 
led to calls for approaches that reduce delays in dis- 
charging patients and lessen the need for people to be 
admitted to hospital in the first place. These aims are 
ably met by OHPAT strategies. This consensus state- 
ment aims to advise those healthcare workers and 
managers on how best to develop, fund, implement and 
evaluate a new or existing OHPAT program. 
OVERVIEW 
Recent developments in clinical technology and 
expertise, coupled with consumerist pressures for 
individual, high-quality health care and diminishing 
healthcare budgets [1,2], have combined to make the 
delivery of outpatient and home parenteral antibiotic 
therapy (OHPAT) an attractive possibility for iniprov- 
ing patient care. Delivered by healthcare personnel, 
carers or patients themselves, in the domestic setting 
or in the hospital as outpatients, these therapies now 
provide a distinct option for patients and their physicians. 
Whatever the initial attraction in terms of height- 
ening patient independence, the practical implement- 
ation of OHPAT requires careful consideration of a 
number of clinical and organizational issues. These 
issues were explored in workshops in London on 25 
March and 3 September 1997. The members of the 
workshops included key experts involved or interested 
in OHPAT, comprising a broad multidisciplinary group 
of primary care physicians, microbiologists, hospital 
physicians with an interest in infection, primary care 
and hospital nurses, pharmacists, health service strat- 
egists, health service managers, patient representatives 
and medico-legal experts. 
Guidelines already existed, from Canada [31 and 
more recently from the USA [4]. The deliberations of 
the group concentrated on sharing experience, primarily 
from the UK, but also adapting existing guidelines 
for local use. The results of the two workshops and 
subsequent detailed discussion between members of 
the group resulted in the development of an OHPAT 
consensus statement aimed niainly at UK practice, and 
are presented here for further discussion and develop- 
ment. 
THE US PERSPECTIVE 
OHPAT progranis (referred to as conimunity-based 
parenteral anti-infective therapy, CoPAT) in the USA 
have R well-developed infrastructure and deliver a high- 
quality service to a large number ofpatients [4,5]. A set 
of guidelines commissioned by the Infectious Diseases 
Society of America (IDSA) details current trends in 
CoPAT 141. These guidelines reveal that many elements 
of European OHPAT practices are developing along 
similar lines to US programs. A number of areas are 
covered by these and act as a useful checklist for con- 
sideration when discussing OHPAT services in Europe 
~41: 
0 
0 
0 
0 
0 
0 
0 
0 
patient evaluation and selection criteria; 
key elements for a community-based parenteral 
anti-infective program; 
the roles and responsibilities of the multidiscip- 
linary team members; 
clinical aspects of care (including monitoring); 
anti-infective selection and administration; 
outcome measures; 
economic considerations; 
risks and benefits. 
THE EUROPEAN PERSPECTIVE 
While the guidelines commissioned by the IDSA [4] 
show many similarities between US CoPAT arid 
European OHPAT activities, the extent of European 
efforts is limited to a few clinical enthusiasts working 
without national support towards the development, 
implementation and funding of such programs [6]. 
The potential benefits to be gained from OHPAT 
programs, and the large size of the potential patient 
group that could be treated using this type of therapy, 
suggest that we should be investing in a more 
organized strategy development in Europe [5]. 
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Barriers to effective development of OHPAT 
programs in Europe might include [5]: 
political and cultural reluctance to consider any 
healthcare innovation in many European coun- 
tries; 
diversity of healthcare infrastructure-for 
example, in France and Germany healthcare is 
mainly hospital-led, while in the UK, The 
Netherlands and many parts of Scandinavia there 
is a strong primary care structure; 
a lack of good clinical and economic data rele- 
vant to each country’s healthcare system; 
organizational issues, including unresolved fund- 
ing issues, level of responsibility and delivery of 
care; 
lack of the intravenous route as a ‘standard of 
care’ and, thereby, underestimation of the need 
for OHPAT; 
low government and clinician priority; 
lack of national guidelines. 
In the UK there is a long-standing tradition of high- 
quality community care with a sophisticated, well- 
established infrastructure. Hospital experts working in 
close association with those in primary care should 
ideally form the basis of future OHPAT programs. 
We should build on the existing experience of com- 
munity intravenous therapy for chronic or recurrent 
infections [6]. This paper is aimed at all interested 
parties who are either actively participating in deliver- 
ing OHPAT or considering developing such programs. 
They aim to identify the key considerations in develop- 
ing, implementing and evaluating OHPAT programs so 
as to provide a high-quality service that is cost-effective, 
safe and, above all, respected by patients and their 
carers. The objective of OHPAT must be to provide 
‘treatment that is equivalent to inpatient therapy if not 
superior’. 
We make recommendations about which patients 
and which diseases are amenable to OHPAT, by whom 
and how the service could be delivered, and what the 
key organizational issues are, including funding, 
pharmacy and recommendations related to quality 
assurance and medico-legal issues. 
WHICH DISEASES ARE AMENABLE TO OHPAT? 
In general, OHPAT can be considered either after a 
period of hospital assessment and stabilization, or 
directly, without hospital inpatient admission. Patients 
with unstable ‘high-risk’ infections such as meningitis, 
endocarditis, severe pneumonia, severe arthritis or 
septicemia should usually be hospitalized initially. 
However, many ‘low-risk’ infections can be managed 
directly by OHPAT [7]. These include: 
infections in cystic fibrosis 18-lo]; 
chronic bone and prosthetic joint infections 
‘low-risk’ neutropenic fevers [15-20]; 
cytomegalovirus (CMV) infection in immuno- 
compromised hosts [21-231; 
skin and soft tissue infections not amenable to 
oral therapy [24,25]. 
[Il-141; 
When a decision is being made about which 
diseases are suitable for OHPAT, a useful distinction can 
be made between acute, chronic and intermittent 
treatment needs. Initially, the main focus for home- 
based antibiotic therapies is likely to be on the chronic 
conditions, where this form of service delivery is easier 
to organize and the benefits are more obvious. 
Although each of the disease areas offers opportunities 
for this type of treatment delivery, a number of 
contextual issues must be recognized as crucial for any 
decision to initiate home-based therapy: 
the antimicrobial activity of prescribed drugs; 
anticipated adverse effects of prescribed drugs; 
the frequency of treatment required. 
Recommendations: bacterial infections 
Much of the literature on OHPAT concerns the 
treatment of bacterial infections, particularly those that 
require several weeks of therapy to ensure cure. These 
prolonged courses of therapy in patients who are often 
not acutely unwell are ideally suited to outpatient 
treatment. However, numerically there are more cases 
that require only a few days of intravenous therapy 
compared to those needing weeks of treatment. 
Infections requiring at least 2 weeks of intravenous therapy 
1. Infective endocarditis is the paradigm for these 
sorts of infection [26]. Although details of 
treatments vary according to the infecting 
organisms and their sensitivities, intravenous 
antibiotics may be necessary for 2-6  weeks. 
Clinically stable patients who are not likely to 
require surgery can be safely treated at home. 
Patients need careful assessment of their cardio- 
v.ascular status as well as assessment of their 
infection. 
2. Osteomyelitis and other orthopedic infections 
[I  1-14]. Osteomyelitis is another condition that 
may require 4-6 weeks of intravenous therapy. 
Patients are usually stable but may have limited 
mobility or pain that precludes discharge. 
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However, patients with osteomyelitis who are 
not limited in this way are ideal for outpatient 
or home therapy. Within this group would 
be included patients with prosthetic joint 
infections or with pathogens resistant to orally 
available antimicrobials (e.g. methicillin-resist- 
ant Staphylococcus aureus (MRSA), coagulase- 
negative staphylococci). Other orthopedic 
problems that may require several weeks of 
intravenous therapy include septic arthritis, 
vertebral discitis, infected metalwork in trauma 
cases, and infection following spinal surgery. 
3. Vascular graft infections constitute another 
group that can be dealt with partly out of 
hospital. These are more complicated than 
the orthopedic infections discussed above, as 
surgical debridement is not possible in the 
same manner. However, prolonged intravenous 
therapy may lead to better outcomes in vascular 
infections [27]. 
4. Abscesses and difficult skm and soft tissue 
infections: a variety of abscesses in neurosurgical 
patients and some difficult skin and soft tissue 
infections [23]. These will include some cases 
of highly resistant microbes and/or multiple 
antibiotic allergies. Some patients may be 
mobile and clinically stable after a week or 
so, but still require a further 2-3 weeks of 
intravenous therapy; these cases include liver 
abscesses, psoas abscesses and brain abscesses. 
5. Patients with cystic fibrosis and bronchiectasis 
[8-101 constitute a special group. They often 
require 10-14 days of parenteral antipseudo- 
monal treatment on a recurrent basis. Once 
venous access is assured, many of these patients 
may be treated at home when chest infections 
occur. 
Infections requiring less than 2 weeks ofintravenous therapy 
The majority of patients in most hospitals require only 
short courses of intravenous antibiotics to achieve a 
cure. Some of these may require hospitalization for 
reasons other than infection but some may remain in 
hospital purely to complete their intravenous therapy. 
1. Soft tissue infections, complicated urinary tract 
infections, pneumonia, meningitis and bac- 
teremia [28]. Soft tissue infections, such as 
cellulitis, probably account for the largest 
number of patients who remain in hospital 
purely to complete their intravenous therapy 
but could be treated at home 1291. Other 
conditions include complicated urinary tract 
infections, pneumococcal pneumonia with 
bacteremia, meningitis (after initial response) 
and S. aureus bacteremia. 
2. Neutropenia and fever following cancer 
chemotherapy [15-201: some patients are at  
low risk of complications but require therapy 
until the fever subsides or the neutrophil count 
recovers. It  is possible to treat these cases as 
outpatients, though careful clinical appraisal and 
follow-up is required. 
Recommendations: viral infections 
1. CMV retinitis, which mainly occurs in patients 
with AIDS, initially required induction and 
then lifelong maintenance therapy with intra- 
venous ganciclovir or foscarnet [21,22]. This is 
best achieved in an outpatient setting, largely 
because of the indefinite duration of therapy. 
The advent of oral ganciclovir and intravitreal 
treatments, however, has reduced the need for 
intravenous therapy. Paradoxically, new drugs 
may still need to be given by the intravenous 
route, though the intermittent-dosing schedule 
is best suited to the outpatient setting. An 
example of this is cidofovir for AIDS CMV 
retinitis. Also, more effective anti-HIV drugs 
may reduce the incidence of CMV retinitis. 
2. CMV disease as it occurs in organ transplant- 
ation may, from time to time, require intra- 
venous therapy with the caveats above. 
3. Varicella zoster virus (VZV) infections in 
immunocompromised hosts, such as those 
undergoing cancer chemotherapy, may need 
prolonged antiviral treatment to heal skin 
lesions and prevent dissemination. Initially, 
intravenous acyclovir was the only reasonable 
treatment option and could be administered at 
home or in the clinic. Foscarnet has been used 
in the outpatient setting for acyclovir-resistant 
herpes simplex infections. The introduction of 
valaciclovir and famciclovir, both of which are 
well absorbed orally and give good plasma 
antiviral levels, has reduced the requirement for 
intravenous acyclovir. 
4. Herpes simplex virus (HSV) encephalitis should 
be treated with intravenous acyclovir for 3 
weeks. Mild cases with rapid responses to 
therapy could be managed partly as outpatients. 
The role of the newer oral agents in this setting 
is as yet unclear. 
Recommendations: fungal infections 
1. Some fungal infections that occur in the setting 
of AIDS and oncology require an initial period 
of intravenous amphotericin B (including lipid- 
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associated preparations) to maximize outcomes. 
This has primarily been shown for HIV-related 
cryptococcal meningitis, but could equally 
apply to histoplasmosis or coccidioides infec- 
tions. It also applies to the longer-term manage- 
ment of Aspergillus and Candida infections in 
oncology patients (e.g. invasive aspergillosis and 
hepatosplenic candidosis). 
2. Pneurnocystis carinii pneumonia (PCP) may be 
treated with intravenous pentamidine, and mild 
cases may not need admission. Equally, monthly 
PCP prophylaxis can be given as regular in- 
fusions of intravenous pentamidine to out- 
patients. 
WHICH PATIENTS ARE APPROPRIATE AND HOW 
ARE THEY 'SELECTED? 
When the suitability of patients for OHPAT is con- 
sidered, a complex set of overlapping and interdepend- 
ent issues is uncovered. These include: 
clinical issues; 
non-clinical issues. 
Clinical issues 
An early and thorough assessment of any patient being 
considered for OHPAT is essential, to ascertain if the 
patient is suitable and the treatment is manageable and 
appropriate for the community. The assessment and 
discharge planning process should be multidisciplinary 
and should include the following people [S]: 
clinician; 
hospital nurse; 
microbiologist; 
pharmacist; 
community liaison nurse; 
general practitioners; 
community nurse; 
0 patient and carer; 
social worker. 
This is ideally done through an integrated care pathway 
[30]. Such a pathway has been developed in Dundee 
and is currently being piloted in Dundee (D. Nathwani, 
personal communication). There should be clear 
documentation of assessment and discharge planning 
in the medical and nursing notes. The general practi- 
tioner (GP) should be contacted at the assessment stage 
to approve the patient being discharged into the 
community. To ensure good service delivery, the 
GP/primary healthcare team needs to be: 
broadly positive towards this form of service 
delivery; 
aware of any patient receiving home-based 
therapy; 
technically competent to advise and assist. 
Important considerations at this stage include the 
following: 
Does the patient want to be at home while 
having this treatment? 
Does the patient/carer/family understand the 
implications of the treatment, the vascular access 
device, how to recognize and deal with any 
complications and who to contact throughout 
the night and day? 
Is there any relevant past medical history? How 
long has the patient been on the treatment and 
have there been any problems/side effects so far? 
Is the treatment appropriate and manageable 
for the community? Is there a treatment plan, 
including a start and finish date? 
Will any blood monitoring be required, for what 
and how often, and who will assimilate the 
results? 
What equipment and supplies are required and 
from where will they be supplied? 
What are the hospital follow-up arrangements? 
Is the GP happy to accept the patient being at 
home for this treatment? 
What level of support and involvement are the 
community nurses and GPs able to provide? 
Non-clinical issues 
Patient's home circumstances 
The patient's home circumstances should be taken into 
account. There should be basic sanitation with running 
water and power for heating and lighting. The patient 
should be able to maintain a reasonable standard of 
personal hygiene at home so that the infusion and line 
are not compromised. Drug or alcohol dependency 
may militate against home therapy. AU patients should 
be registered with a GP and have access to a community 
nurse. The patient should have access to a telephone, 
ideally on the premises, for use in emergencies and for 
accessing help. In many but not all circumstances, access 
to a refiigerator is helpful, particularly if pre-diluted 
drugs are supplied. Some form of family support or on- 
site carrr is a clear benefit, though not absolutely 
necessary. However, for the old or frail patient, such 
support is mandatory. Finally the patient's home must 
be within reasonable reach of the hospital for easy 
outpatient attendance and rapid assessment in case of 
emergencies. Ideally, the home should be less than an 
hour's travel by road from the hospital or clinic. 
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Attitudes, preferences and values 
When non-clinical issues relevant to determining 
which patients are suitable for OHPAT are considered, 
a complex set of attitudes, preferences and values is 
uncovered, mainly centered around two issues: 
Attitudes and preferences about hospitalization 
in patient groups. These include the individual 
patient’s desire to go home for treatment, their 
competence and ability to support themselves at  
home, the presence of an appropriate home 
environment to support this and, above all, their 
belief that home therapy provides quality of care 
that is equivalent to hospitalization. 
Cultural and professional values and interest 
among local healthcare groups. For example, 
hospital specialists may view OHPAT as a threat 
to their beds, i.e early discharge may reduce the 
need for and, possibly, the funding for some 
hospital beds. GPs may, in turn, feel that the 
hospital is putting an added burden on the 
community for high-technology care that they 
cannot manage. There is also a risk that patients 
may be discharged early on inappropriate oral 
therapy to reduce bed pressure, or patients and 
conimunity health groups may be forced to 
accept non-inpatient parenteral therapy without 
sufficient education, planning or infrastructure. 
Recommendations: which patients are suitable for OHPAT? 
1. The patient being considered for OHPAT must 
have a disease that requires intravenous anti- 
biotics. 
2. The antibiotic regimen should be feasible for 
outpatient use (some complicated regimens can 
only be administered if programmable infusion 
pumps are available, for example). 
3. The patient should be clinically stable, so that 
the likelihood of emergencies or deterioration 
is low. 
4. Apart from the requirement for intravenous 
antibiotics, the patient should be medically and 
psychologically fit for discharge. He or she 
should understand and consent to the discharge 
plans. 
5. The views and agreement of the GP and 
community nurse (if applicable) should be 
obtained. 
WHAT ARE THE PHARMACY ISSUES? 
Effective pharmacy services play a key role in the success- 
ful development, planning, provision and monitoring 
of an OHPAT program. The availability of the right 
drug, in the right form, and in the right place, is 
crucial. Pharmacy services may be provided by the 
hospital, community, or both. Pharmacy irsues in  
OHPAT can be divided into three areas. 
Drug selection 
The pharmacist should be integral to the development 
and/or assessment of an appropriate treatment plan for 
each infection inanaged by an OHPAT program, and 
for each individual patient. The pharmacist’s role 
includes input in selecting the appropriate drug, the 
appropriate dose, and the appropriate route and 
means of administration. Drug properties that should 
influence selection by the pharmacist for an OHPAT 
antibiotic regimen include: 
antimicrobial activity; 
efficacy in clinical trials; 
half-life and/or duration of therapeutic agent; 
side effects; 
cost-effectiveness. 
Drug delivery 
Appropriate delivery of the drug to and into the patient 
are integral to drug delivery. Properties that the 
pharmacist should consider for an OHPAT antibiotic 
regimen include: 
cheniical stability-to minimize dispensing fre- 
quency and storage/transportation problems; 
compatibility with other drugs and admixtures; 
suitable administration devices; 
ease of administration. 
Drug funding 
The cost and funding of antibiotic therapy should not 
be viewed in isolation from other components of an 
OHPAT program or indeed from alternative options 
for the provision of treatment. 
Recommendations: pharmacy issues 
1. The local implementation of pharmacy services 
should involve both nurses and pharmacists in 
an integrated role. 
2. For recornrnendation 1 to occur, some clear 
training needs must be addressed. The conven- 
tional pharmacy role involves little direct 
contact with dependent clientdcarers, such that 
the appropriate communication skills need to 
be developed. Pharmacists would also need 
training in monitoring the drug requirements of 
home-based clients over time. 
3. GPs need to be more closely involved in and 
aware of the issues surrounding and techniques 
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used in home-based pharmacy and drug pro- 
vision. 
4. There remain differing views on the most 
effective degree of devolution of pharmacy 
services. The two main options (not mutually 
exclusive) are as follows: 
The pharmacy is hospital-based (where 
expertise is concentrated), but the pharmacy 
is advised by community specialists, to enable 
it to respond to local conditions. An illus- 
tration of this is the variation in equipment 
needed between hospital and community 
settings. Portable drug pumps and their 
associated specialist provision are not as 
significant in the hospital setting, for example, 
where patients are largely stationary in beds. 
Pharmacy and prescribing should be co- 
ordinated at a hospital level, but with strong 
input and advice from local GP purchasing 
or commissioning groups, and practice/com- 
munity nursing staff. 
WHAT ARE THE ISSUES AROUND DISCHARGE 
PLANNING? 
Discharge planning is an integral part of the assessment 
process and should continue until the patient is 
discharged from hospital. Ideally, it should be one 
person’s responsibility to coordinate and monitor the 
plan. Included in the plan are the following sections: 
0 
0 
Table 
how communication and liaison with patient/ 
carer/family, multidisciplinary team and primary 
healthcare team is maintained; 
treatment plan-duration of treatment, the date 
when the drugs were started and finished, a 
record of hospital follow-up and review; 
details on storage and preparation of drugs and 
diluent for the patient/carer; 
organization of the provision of drugs, equip- 
Information that needs to be included is summarized 
in Table 1. 
ment and ancillary items. 
HOW CAN OHPAT BE DELIVERED? 
Home- or outpatient-based antibiotic therapies are 
amenable to delivery by several different parties; the 
various models of care currently used in the UK are 
summarized in Figure 1 [5]. Regardless of the model, 
the core members should include a physician with 
an interest in infection, a nurse, a pharmacist, the 
patiendcarer and, where required, a social worker. The 
prescribing physician should coordinate care and be 
ultimately responsible for the delivery of the patient’s 
care. However, each model of OHPAT delivery in the 
UK has various strengths and weaknesses, which are 
summarized in Table 2. In the UK it may be preferable 
to use the existing well-established network of district 
nurses as the primary focus of delivery of OHPAT. The 
system should be flexible to allow patients or carers 
to administer treatment if appropriate. Other models 
are equally valid and may be preferable in different 
healthcare systems elsewhere in Europe. 
Recommendations: issues surrounding who should deliver 
OHPAT 
1. ISducation/training of various parties is essential. 
2. I’atient/carer education and training must have 
high priority, and should cover: 
drug information; 
administration details; 
handling of equipment; 
0 possible side effects; 
0 care oflines; 
0 importance of compliance; 
system for obtaining help. 
All information should be given in verbal and 
written form. 
1 Checklist of information to be included in the discharge plan. _ _  
Patient Vascular access device Treatment 
Relevant past medical history and allergies 
Dosage regimen for the individual 
Problems/side effects experienced 
Frequency and timing of clinic visits Possible complications-signs, symptoms, regimen 
during treatment prevention and management Side effects 
Blood monitoring and frequency 
Time on treatment with the device Admmistration details 
Finish/review date for treatment 
How to access help 
Type of device 
When inserted or placed, and by whom 
If centrally placed, where is the tip? 
Pathology and infecting 
Details of antibiotic 
organism 
Who to contact if there are any dificulties 
Who will remove the device and how 
Monitoring requirements 
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Hospital Core Team 
Clinician with interest i n  
infect ion 
Nurse with i i n  interest in 
IV therapy 
Hospital phiirmacist 
Patient attends 4 C Patientlcarer trained 
outpatient clinic ' in the ward to . -  administer IV or day unit I - - - - - - - - - - 
I therapy 
I 
I I I I 
I 
I 
I 
I 
I 
I 
I 
infusion 
companies 
Devolve to GP 
or community 
hospitals 
Community District - - - - - - 
I 
I 
I 1 
Self-administer 
IV therapy at home Administer IV _ _ _ _ _ _ _ _ _ _ - - I  
therapy to patient 
Figure 1 Current UK models for delivering OHPAT antibiotics. 
IV. intravenous. 
3. Nursing groups in the community (district, 
practice nurses, etc.) are a key resource, but need 
theoretical and practical training and support. 
4. Overall delivery of care needs to be organized by 
a coordinator, with 24-h on-call systems in place. 
5. Early and systematic assessment and discharge 
planning in the hospital smooths the transition 
into community/home-based care. 
6. The overall direction and form of all home- 
based services should be coordinated at a Health 
Authority/Board or regional level. 
HOW SHOULD OHPAT PATIENTS BE MONITORED 
DURING THERAPY? 
Recommendations: monitoring and follow-up 
As part of the discharge planning process, a manage- 
ment plan specific to the infection treated and the 
patient's needs should be produced. It  is suggested that 
this plan includes the following elements: 
1 .  A review of the site of care (home, outpatient 
clinic, day, day ward, etc.). 
2. Identification of the role and degree of involve- 
ment of all healthcare professionals. 
3. Patient information and education to be pro- 
vided (e.g. coping with potential problems, wors- 
ening of infection, intravenous access problems). 
4. The frequency of patient review/follow-up 
(this will be determined by the disease and 
stability of infection). 
5. Details of arrangements for 24-h access to 
professional care (on-call unit). 
6. Parameters to be monitored (e.g. clinical, labor- 
atory economic). 
7. A communication plan that facilitates a rapid 
flow of information between team members 
delivering the service and feedback to all meni- 
hers of the team. 
8. Proper documentation of information. 
HOW CAN PATIENTS OBTAIN HELP DURING 
THERAPY, AND WHAT IS REQUIRED TO PROVIDE 
SUCH HELP? 
It  is essential that patients receiving parenteral therapy 
outside the hospital setting have easy access to help 
when required: for information, for reassurance, or for 
emergencies. To some extent, the way this is organized 
depends on the model being used to deliver OHPAT. 
During working hours (9.00 a.m. to 5.00 pm.),  the 
patient should have a contact telephone number for the 
health worker administering the intravenous antibiotic 
(i.e. the community nurse in the UK) or the OHPAT 
coordinator. The health worker can then contact a 
named person within the OHPAT team, the hospital 
or the GP, as appropriate. Outside these hours the 
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Table 2 Strengths and weaknesses of different deliverers of OHPAT 
OHPAT deliverer Strengths Weaknesses 
Patientdcarers Patient autonomy 
Methodical, and technique good 
Available 24 h/day 
Need for individualized training which is time-consuming 
More difficult to monitor patientlcarer technique in the 
Loss ofpatients’ perceived ‘sick role’ 
and could delay chscharge 
community 
Community nurses Based and working in the community 
Can provide a service 7 days a week 
Day and night service in some areas 
Able to monitor patient 
Resource implications for training and ongoing support 
Intravenous therapy regimen may mean that several 
nurses are involved in administration-loss of continuity of care 
Practice nurses 
GPs 
Based in the community (usually a 
Ready access to prescribing facilities 
Able to monitor patient 
Patients visit health center (encourages 
One or two nurses involved 
Based and working in the community Resource implications for training of all GPs in the practice 
Patient monitored by medical practitioner Limited resources and time available 
Ability to admit patient to hospital if needed Not su’stainable for: 
Patient has to visit health center 
Resource implications for training and ongoing support 
Generally 5-day service during daytime and some early evening 
health center) 
independence) 
Long-term treatment 
Frequent dosing 
More than one or two patients on treatment at any given time 
Commercial organizations Able to provide flexible service from Cost implications 
experienced nurses 
Able to monitor patient 
24-h helpline 
Regular monitoring of patient 
Accessible medical back-up 
Outpatient departments 
Possible loss of holistic care focus 
Not directly involved in patient management 
Patient has to travel 
Five-day service during daytime 
Hospital ‘outreach’ teams/ Able to monitor patient Not sustainable for: 
specialist nurses Experienced nurses with access to Long;-term treatment 
hospital medical support Frequent dosing 
Long distances 
Large numbers of patients 
patient needs access via the telephone to an on-call 
liaison nurse, doctor or ward familiar with OHPAT, 
antibiotics, lines and the patient. 
In addition to contact numbers, a simple algorithm 
of whom to call and when should be provided and 
discussed with the patient before discharge. For a 
successhl OHPAT scheme, the patient should be able 
to obtain help 24 h a day. 
WHAT FOLLOW-UP ARRANGEMENTS ARE 
NECESSARY? 
Appropriate medical supervision is required for all 
patients receiving OHPAT. Close monitoring by the 
physician ensures that the infection is responding to 
the prescribed treatment and that co-morbid illness is 
also monitored. In addition, the physician can observe 
adverse reactions to the treatment and, with the liason 
nurse, check that the intravenous line is in a satisfactory 
condition and that the patient is well supported. 
Patients should be seen by the physician and liaison 
nurse weekly or 2-weekly during therapy. Routine 
blood tests (biochemistry, full blood count, and 
inflammatory markers) can be obtained from the 
patient at home, but medical staff at  the clinic/hospital 
need to take responsibility for monitoring the patient’s 
results. There needs to be a plan for responding to any 
abnormal results. At the end of the planned treatment 
course the patient needs to be reviewed to ensure that 
sufficient therapy has been given to eradicate the 
infection, or that there is a switch to oral therapy if 
appropriate. Finally, at the end of therapy the intra- 
venous line may need to be removed by someone who 
has been trained in this procedure. Individual patients 
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with clinical problems should be followed up at the 
appropriate clinics. 
QUALITY ASSURANCE AND AUDIT 
The quality of medical care in the home or outpatient 
setting should be as high as or higher than in hospital. 
Advances in technology have made it possible to 
manage many of the infections that need parenteral 
antibiotics in the outpatient and home setting. This 
concept of such care in infectious diseases is relatively 
new and untried in the UK, so providers of OHPAT 
must manage a certain level of risk. These risk factors 
differ from those present in hospital practice; they 
need to be identified and their relative importance 
determined. This is best done as part of an integrated 
quality assurance program that includes measuring 
process and health outconies and audit. 
Quality in medicine is: 
defining standards of care; 
reviewing those standards periodically; 
continuously improving the medical systems that 
support these standards. 
In other words, quality defines 'the extent to which 
care provided is expected to achieve the most favour- 
able balance of risks and benefit' [31,32]. Any quality 
assurance model should include the 'six dimensions 
of quality' expected in health care [33,34]. These 
principles applied to OHPAT are described in Table 3. 
The structure of a service, the process through which 
the service is delivered and outcome parameters can be 
assessed against each of these quality criteria [35,361. 
One of the most important aspects of OHPAT, for 
example, is patient selection (i.e. the process by which 
patients are informed of the service/seek advice/are 
referred to the service). This process ofselection can be 
Table 3 Thc 'six dimensions of quality' expected in 
health care 133,341 
Quality dirncmion Applying the principle to OHPAT 
Efikctivenesa Is the treatment adininicered in OHPAT the 
best mailable? 
Acceptability 
Effclcnc)- 
Access 
How hurrianely and considerately is the 
Is the output maximized for a given input? 
Can people get the treatment/scrvice when 
Are OHPAT patients trcated fairly relative to 
Is the overall model of the service provided 
treatment/service delivered? 
they nccd it? 
others? 
the best that could be achieved for a 
particular locality? 
E qu i ty 
Kelcvance 
assessed to be effective, acceptable, efficient, equitable 
and relevant by including a step in which key infor- 
mation about the quality indicators of the selection 
process is incorporated. 
In the USA, the Joint Commission on Accredit- 
ation of Health Care Organizations UCAHO) Home 
Infusion Task Force has designed six clinical indicatorc 
to facilitate collection of data regarding significant 
clinical events [37]. However, these indicators are not 
specific to OHPAT, have not been confirmed as reliable 
or valid, and primarily assess quality of structure and 
function of the organization rather than outcome 1381. 
However, in these particular areas they will identifv 
problem areas which could then be addressed through 
further development. Increasingly, monitoring and 
measuring clinical outcomes is viewed as a good way 
to assess the true impact of any model. Some of these 
have recently been suggested by those involved in the 
Outpatient Intravenous Infusion Therapy Association 
(OPIVITA) [38,39]. 
In the UK there are intrinsic weaknesses in 
establishing uniform criteria for OHPAT, as follows: 
There is no established infrastructure for 
OHPAT. It  tends to be carried out in isolation 
and independently. 
Information technology is poorly developed- 
a culture of good documentation of structure 
and process does not exist except for nursing 
care. 
Data retrieval is difficult due to a lack of coni- 
puterization/database facilities. 
Currently available outcome parameters are 
crude (e.g. for death, length of hospital stay, 
readniission rates). 
Focus tends to be on output rather than out- 
come. 
Difficulties arise when utilization reviews are 
attempted, as individual items are often not 
priced and contacts between trusts and primary 
care physicians vary considerably. 
Those in the UK considering developing OHPAT 
programs have a golden opportunity to establish clear 
criteria at  the outset, to ensure a quality system that is 
shared, timely, sensible, viable and understood. These 
criteria should be subject to continuous audit to 
improve the clinical effectiveness of the service (401. 
Integrated care pathways [30] comprise an ideal process 
to document and subsequently evaluate the quality of 
OHPAT. They have many advantages but primarily 
facilitate the introduction of guidelines, with a syste- 
matic and continuing audit, into clinical practice. 
improve niultidisciplinary communication and care 
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planning, reach or exceed existing practice quality 
standards, decrease unwanted practice variation, im- 
prove clinician-patient communication and identify 
research and development questions. 
Recommendations: quality assurance and outcome 
measures 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
Define clearly the roles and expectations of all 
members of the team. 
Involve patients in the decision-making process 
and evaluation of the service. 
Define clear guidelines/protocols for all stages 
of the process (integrated care pathways are ideal 
for OHPAT). 
Improve the collection, documentation and 
retrieval of information. 
Introduce specific and measurable objectives for 
the service. 
Use simple, measurable and clinically applicable 
outcome criteria. 
Adapt the principles of the quality assurance 
model described to individual services. 
MEDICO-LEGAL ASPECTS OF OHPAT CARE 
These issues do not differ fundamentally from those 
surrounding hospital care. As OHPAT is relatively new 
and not yet defined in terms of ethics, regulations and 
the law, it is advised that a number of issues related to 
the law are identified and addressed. A realistic method 
of risk management, comparing the problem of 
community with that of individual care, should include 
clearly defined areas of responsibility and a hierarchical 
structure to identify and define: 
the roles of all healthcare workers; 
aspects relating to drugs and equipment 
(including reference to the Dangerous Drugs 
Act [41]); 
consent to treatment. 
These legal issues should be included in any contracts 
between purchasers and providers. 
Recommendations: legal issues 
1. The roles and responsibilities of all healthcare 
workers (consultant, junior staff, GP, com- 
munity nurse, pharmacist), and their profes- 
sional liabilities, levels of competence, extent of 
training and experience, must be established 
and recorded for audit, efficacy and cost- 
effectiveness monitoring. 
2. Aspects of care relating to drugs and equipment 
need to be clarified and documented. These 
include product liability, licensing of drugs, 
3. 
long-term use of parenteral preparations, safety 
;and security of drugs, Dangerous Drugs Act 
[41], safety and disposal of sharps, availability 
of antidotes for anaphylactic reactions, and 
resuscitation equipment. 
Consent to treatment must be recorded in 
;accordance with clear guidelines when obtain- 
mg and documenting consent (the consent 
for research and trials differs from the consent 
to established treatment regimens). In ongoing 
management of the long-term sick, the recog- 
nition of the changing or withdrawing of 
consent must also be considered. 
FUNDING ISSUES RELATED TO OHPAT 
The management of OHPAT is organized informally 
by enthusiasts. The cost and benefit information on 
which purchasers/providers can base a decision to 
support its corporate development, therefore, is not 
readily available in the UK, although, recently, 
interesting information which is of value to decision- 
makers in the UK has begun to emerge [42,43]. 
However, there is an abundance of fiscal information 
available, mainly from North America, illustrating clear 
economic benefits, but these analyses are less relevant 
to European health care [44]. For many aspects of 
modern health care, particularly new initiatives, a 
variety of issues need to be resolved. This is also true 
of OHPAT: 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
It occurs over many specialities. 
It is not recognized as a big issue, except by those 
managing it. 
The numbers per natural catchment population 
are not great. 
It is not the subject of a research and develop- 
ment program. 
It is not part of the guidelines of any nationally 
recognized professional body. 
The service has not been specified. 
Costs have not been identified separately. 
No service specifications or service-level agree- 
ments exist. 
Current services have developed in an ad hoc 
manner. 
It is a developing health technology. 
However, some of these issues are not insurmountable. 
Business issues 
When the establishment or integration of current 
piecemeal arrangements for a non-inpatient intra- 
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venous antibiotic service is considered, a business case 
will need to be made. Important factors will include: 
the numbedproportion of current hospitalized 
patients who might be treated; 
the current costs of their inpatient treatment; 
the cost of providing alternative treatment; 
requirements for other intravenous therapies 
(e.g. total parenteral nutrition or cancer chemo- 
therapy). 
In addition, long-term funding may only be 
achieved through collaboration with GPs [43], and in 
particular GP Commissioning Groups. 
Numbers of patients 
The estimated UK population receiving OHPAT is 
shown in Figure 2. This translates into approximately: 
110 000 bed-days per year; 
or 301 beds; 
or three beds per Health Authority (Board). 
Unfortunately, these relatively small numbers may not 
gain the necessary support and commitment from 
Health Authority purchasers, despite the potential to 
increase cost/efficiency under the EL(9S)S directive [4S]. 
The introduction of Primary Care Groups (or GP 
Commissioning Groups) in 1999 may address current 
concerns about accident and emergency admissions, 
availability of beds, and waiting lists. However, the 
/..'..I\ practice 
/ r - z E j r l \  Commissioning Group 
501200 per Healfh Authority / rTzi-- \ 
Figure 2 Estimated number of the UK population 
receiving OHPAT. 
provision of home intravenous therapy and OHPAT 
will continue to have a lower priority unless GPs and 
health service managers are convinced of the benefits 
of OHPAT and are able to commit the necessary 
resources to the development of OHPAT schemes. 
Potential savings 
Even if maximum efficiency could be achieved by 
managing all cases on a non-inpatient basis, the 
following factors would mitigate the savings: 
At least 40% of the institutional costs remain as 
overheads (mainly fixed) [46]. 
The savings for a GP-based service as opposed 
to a hospital-based service are likely to be 
small [47]. 
It is likely that the costs for a GP-based service 
as opposed to a hospital-based service for this 
type of work could be higher [40]. 
Therefore, based on the nunibers of patients treated and 
the costs of providing the service, it is unlikely that 
economies of scale or place of treatment could be 
shown to create savings. Indeed, Scott found that, 
'at the moment, the evidence on the efficiency of 
providing secondary-care services in a primary-care 
setting is limited and inconclusive' 1471. However, since 
the implementation of EL(9S)S a number of initiatives 
have required shifts of services and hence resources 
from hospital to primary care services, which would 
assist in the provision of OHPAT. The scale of transfer 
is unlikely to destabilize hospital trusts. The key issue 
for implementing OHPAT is not cost or saving but 
appropriate use of funds to maximize patient benefits 
and NHS efficiency. 
Favorable indicators 
A number of factors do, however, support OHPAT, as 
folllows: 
Creating settings where primary and secondary 
care need to work on an integrated basis to 
provide care and treatment is being encouraged 
-NHS policy. 
Most patients prefer to receive their treatment 
out of hospital as close to their home as possible 
-listens to patients and carers. 
Treatment out of hospital is the preferred 
model-NHS policy. 
Managing disease under the auspices of experts 
as opposed to a generalist approach is favored- 
NHS policy. 
It is government policy to make primary care the 
focus for NHS decision-making-NHS policy. 
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It offers the opportunity for the purchase of 
‘high-tech’ treatment in partnership with the 
private sector-it shares the risk. 
The practical as opposed to the clinical benefits 
of implementing the above policy themes may sway a 
purchaser or provider to resource the organization of 
antimicrobial therapy on an out-of-hospital basis. 
Policy 
The policy for supporting patients receiving high- 
technology health care at home has been set out in EL 
(95)5--Purchasing high-tech healthcare for patients at home 
[45]. This included patients with renal failure, cancer 
or cystic fibrosis, and those who are HIV positive. After 
1 April 1995, funding for these services was through 
contracts. The policy was set to obtain better value for 
money by encouraging competition between suppliers. 
Contracts and a strategy for purchasing the packages of 
care for patients receiving these services at home were 
set by 1 April 1995; they included hospital at-home 
initiatives [48]. Funds spent through GP prescribing 
were identified and transferred to purchasers’ budgets. 
They included an allocation made to cover the cost of 
people attending open-access clinics outside their 
Health Authority. Health Authorities identified patients 
receiving these services, agreed a detailed specification, 
and ensured that the arrangements offered the best 
value. OHPAT should be part of this policy, and should 
include initiatives to develop a strategy for services 
based on: 
improving health; 
strengthening the coordination of services bet- 
ween primary and secondary care; 
maintaining the NHS services centered on 
primary care; 
creating hnding initiatives designed to encourage 
the primary and secondary care sectors to work 
together. 
The Whlte Papers [49,50] provide a useful founda- 
tion for the establishment of OHPAT services. 
that provision of OHPAT is supportable by the 
existing infrastructure. 
Many GPs will have cared for a patient with cystic 
fibrosis who may have received intravenous antibiotics 
at home from a commercial home-care organization or 
hospital trust before the introduction of EL(95)5 [45]. 
GPs will have fimded this package of care from their 
prescribing budgets. Therefore, OHPAT is not a new 
concept, and those GPs who have seen the benefits to 
the patient and family should be encouraged to act as 
advocates for the OHPAT approach. Considering this, 
it may be that the new Primary Care Groups created 
under the current White Papers [45,49,50] will offer 
the most likely source of funding. 
Sources of funding and key personnel 
There are two main levels of funding-national and 
local. The national fund providers will only act as a 
pump-priming source (via a research proposal) to 
provide evidence that OHPAT is the preferred option. 
Local sources will only fund the proposal iE 
it saves money, or 
the benefits outweigh the costs, or 
it gives the purchaser or the provider an 
opportunity to initiate a national policy and is, 
at least, cost-neutral. 
The fund providers are likely to be Health Authorities 
(Boards), or Primary Care Groups, while adopters are 
likely to be Trusts. Personnel who need to be con- 
vinced of the funding benefits of OHPAT are shown 
in Table 4. 
OHPAT funding may come from the initiative to 
transfer funds from hospital to primary care. Indeed, 
the Joint Investment Fund described in Designed to 
Care [50] could offer an ideal source of funding for 
OHPAT in Scotland. 
Table 4 Key personnel within Health Authorities (Boards) 
and Trusts who need convincing of the cost benefits of 
OHPAT 
Health Authorities (Boards) Trusts 
Convincing those who provide the resources 
In order to convince resource providers to fund 
OHPAT, the following criteria need to be determined: 
the setting (e.g. individual GPs, Primary Care 
Groups, etc.) for provision or purchasing where 
the numbers are sufficient to demonstrate 
evidence of benefit; 
0 evidence, having considered cost and benefit, 
Directors of Public Health 
Directors of Primary Care 
Directors of Finance Speciality Managers 
Commissioning Groups, doctor 
Directors of Business 
Clinical Directors 
and nurse leaders and managers 
of the group Speciality Accounts 
(in medicine, nursing, pharmacy, 
general practice) Trust Medical Directors 
Relevant professional advisors 
Directors of Nursing 
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Recommendations: funding 
1 .  Speci+ the need in a given population (e.g. per 
Z O O  000 population). 
2. Examine critically whether the patient group 
could be expanded to include other intravenous 
therapies. 
3. Specifj (local) integrated care pathways and 
associated protocols (guidelines) so that the 
service can be costed. Evidence of benefit 
should be provided to further the imple- 
mentation of EL(95)S. 
4. Prepare a business case using crude data to 
compare the options for providing the therapy; 
build in economic and evidence-based argu- 
nients if the information exists or can be readily 
derived, and explore the potential benefits of a 
joint venture under NHS guidance. (Note: this 
would take up to 6 months and would probably 
not have the strength of recognized economic 
appraisal or the inforniation on whether the 
change to a rion-inpatient service is a clinically 
significant improvement.) 
J .  Undertake an economic study similar to the 
Scott study 1451. (Note: this may need funds of 
A150-250k and could take 18-24 months to 
6. Prepare a proposal for the National Funding 
Bodies for Research and Development to 
support a Systematic Review (currently A50k 
per review) to see if there is sufficient evidence 
to endorse the practice or whether further 
primary research is required. 
7. Inform opinion leaders, interested individuals 
and organizations-including locality-led GPF, 
NHS regional offices, Comniunity Health 
Councils and local health forums-of the 
conclusions above, using a business case that 
shows that OHPAT is the preferred option. 
(Note: As stated earlier, the new Primary Care 
Groups described in the White Papers [49,50] 
may be the best option for funding. They will 
be established by 1999.) 
8. Engage community nurses and managers of 
Primary Care Groups in the debate so that their 
greater role in the management of services, as 
described in the White Papers 149,501 can be 
used appropriately to promote the development 
of OHPAT. 
complete.) 
CONCLUSION 
There are already numerous examples of OHPAT in 
parts of the UK and Europe. What is lacking, however, 
is a perspective that enables this type of treatment 
option to be developed more widely. Such develop- 
ment, while in line with the UK NHS policy of 
providing high-quality non-inpatient care, also allows 
more flexible and imaginative use of resources for 
hospital and community trusts. I t  is hoped that this 
paper will help those groups wanting to start an 
OHPAT program but will also provide a focus for 
developing and implementing national, and European, 
standards. We have attempted to discuss the various 
coniponerits of OHPAT by drawing attention to the 
potential problems as well as benefits. We believe that 
the strength of this document is the importance it 
attaches to quality iswes and funding, often seen by 
many as a barrier to such innovation. Many of the issues 
discussed are not very different from those already 
confronted by hospitals and conirnunity health groups 
in other areas. Some of the technical aspects of 
administering antibiotics out of hospital are contained 
in an appendix (available on the OHPAT honie page- 
WWW.OHPAT.OKG.UK; PASS WORD-qwac). We 
hope that this document stimulates the proliferation of 
OHPAT in the UK and Europe and proniotes research 
in a rapidly expanding therapeutic area. 
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